Van ECK Associates Corp Sells 15,454 Shares of BeiGene, Ltd. (NASDAQ:BGNE)

Van ECK Associates Corp lessened its holdings in shares of BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 15.7% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 82,696 shares of the company's stock after selling 15,454 shares during the quarter. Van ECK Associates Corp owned about 0.09% of BeiGene worth $14,915,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Toronto Dominion Bank lifted its stake in BeiGene by 166.4% in the third quarter. Toronto Dominion Bank now owns 333 shares of the company's stock worth $60,000 after acquiring an additional 208 shares during the last quarter. Knights of Columbus Asset Advisors LLC grew its holdings in shares of BeiGene by 20.5% during the third quarter. Knights of Columbus Asset Advisors LLC now owns 447 shares of the company's stock worth $80,000 after buying an additional 76 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of BeiGene by 123.9% during the third quarter. PNC Financial Services Group Inc. now owns 732 shares of the company's stock worth $132,000 after buying an additional 405 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in BeiGene by 98.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,078 shares of the company's stock valued at $194,000 after acquiring an additional 536 shares during the period. Finally, Clear Harbor Asset Management LLC purchased a new stake in BeiGene during the 4th quarter valued at approximately $208,000. Hedge funds and other institutional investors own 48.55% of the company's stock.

BeiGene Price Performance

Shares of NASDAQ:BGNE traded up $5.48 during trading on Thursday, hitting $162.01. 268,380 shares of the stock were exchanged, compared to its average volume of 256,365. The company has a market cap of $15.49 billion, a PE ratio of -18.42 and a beta of 0.63. The company has a current ratio of 2.32, a quick ratio of 2.09 and a debt-to-equity ratio of 0.06. The company has a fifty day moving average price of $155.23 and a two-hundred day moving average price of $166.71. BeiGene, Ltd. has a 12-month low of $126.97 and a 12-month high of $266.67.

BeiGene (NASDAQ:BGNE - Get Free Report) last issued its quarterly earnings data on Monday, February 26th. The company reported ($3.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.61) by $0.08. BeiGene had a negative return on equity of 23.12% and a negative net margin of 35.86%. The business had revenue of $634.40 million for the quarter, compared to the consensus estimate of $632.52 million. During the same period in the prior year, the business earned ($4.29) earnings per share. The business's revenue was up 66.9% on a year-over-year basis. On average, analysts forecast that BeiGene, Ltd. will post -8.9 EPS for the current year.

Insider Buying and Selling at BeiGene

In other news, CFO Julia Aijun Wang sold 397 shares of the company's stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $167.08, for a total transaction of $66,330.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO John Oyler sold 37,668 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $164.02, for a total transaction of $6,178,305.36. Following the completion of the sale, the chief executive officer now owns 12,332 shares of the company's stock, valued at approximately $2,022,694.64. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Julia Aijun Wang sold 397 shares of BeiGene stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $167.08, for a total transaction of $66,330.76. The disclosure for this sale can be found here. Insiders have sold a total of 64,781 shares of company stock worth $10,222,381 in the last quarter. 7.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on BGNE shares. JPMorgan Chase & Co. lifted their target price on BeiGene from $184.00 to $186.00 and gave the company an "overweight" rating in a research note on Tuesday, March 19th. Bank of America lowered their price objective on shares of BeiGene from $179.30 to $164.30 and set a "neutral" rating on the stock in a research report on Monday, April 8th. TD Cowen boosted their price objective on shares of BeiGene from $235.00 to $236.00 and gave the company a "buy" rating in a research note on Wednesday, April 24th. Guggenheim reduced their target price on shares of BeiGene from $350.00 to $345.00 and set a "buy" rating for the company in a research note on Tuesday, February 27th. Finally, Sanford C. Bernstein lowered their target price on shares of BeiGene from $196.00 to $161.00 and set a "market perform" rating on the stock in a report on Wednesday, March 27th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $250.13.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.